Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Caporusso

Podiatrist, Foot & Ankle Surgery McAllen, TX Doctor of Podiatric Medicine

NPI 1528062213 CMS profile 68739

812 Lindberg Ave, McAllen, TX 78501

Open in the dashboard

General payments

$289,225

506 records reported · program years 2019–2025

Research payments

$273,563

Paid to them · 57 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,670,033 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Joseph Caporusso of McAllen, TX is reported in the CMS Open Payments database as having received $289,225 across 506 general payments and $273,563 in research payments paid to them. Separately, studies naming them as principal investigator received $5,670,033 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,123 7
2025 Research $1,349 8
2024 General $1,445 3
2023 General $18,624 19
2023 Research $5,701 21
2022 General $82,424 103
2021 General $81,268 158
2021 Research $2,000 1
2020 General $46,781 106
2020 Research $163,113 16
2019 General $57,561 110
2019 Research $101,402 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Caporusso
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Joseph Caporusso were reported at $1,123. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Joseph Caporusso Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $57,561 $389 $118–$1,406 $163
2020 $46,781 $191 $62–$691 $114
2021 $81,268 $329 $104–$1,341 $132
2022 $82,424 $419 $125–$1,611 $149
2023 $18,624 $377 $128–$1,164 $160
2024 $1,445 $394 $134–$1,168 $164
2025 $1,123 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $263,209 437 payments
  2. Ortho Dermatologics, a division of Bausch Health US, LLC $21,249 16 payments
  3. Mylan Specialty L.P. $1,399 5 payments
  4. Endo USA, Inc. $837 4 payments
  5. TissueTech, Inc. $584 2 payments
  6. Horizon Therapeutics plc $423 8 payments
  7. Smith+Nephew, Inc. $231 3 payments
  8. Medline Industries, Inc. $182 2 payments
  9. Melinta Therapeutics, Inc. $162 4 payments
  10. PolarityTE, Inc. $150 2 payments
  11. Other $800 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $116,190 90 payments
  2. Consulting Fee $77,018 37 payments
  3. Travel and Lodging $38,725 232 payments
  4. Honoraria $35,950 19 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $14,175 3 payments
  6. Food and Beverage $7,155 124 payments
  7. Entertainment $12 1 payment
Products named General payments · program years 2019–2025
  1. Puraply $114,378 163 payments
  2. Apligraf Podiatry $56,236 89 payments
  3. Puraply/Affinity/NuTech $56,236 89 payments
  4. Dermagraft $56,236 89 payments
  5. Affinity $50,961 91 payments
  6. Puraply Antimicrobial $30,276 72 payments
  7. JUBLIA $21,249 16 payments
  8. NuShield $8,923 16 payments
  9. Apligraf Wound Care $3,954 6 payments
  10. PURAPLY WOUND MATRIX $1,560 2 payments
  11. Other $7,473 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Integra LifeSciences Corporation $177,831 13 payments
  2. PolarityTE, Inc. $88,684 15 payments
  3. TissueTech, Inc. $5,701 21 payments
  4. Regeneron Pharmaceuticals, Inc. $1,349 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

808

Median for Podiatry: 160

Drug cost

$69,668

Median for Podiatry: $2,368

Branded share of claims

10.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 38 $34,689
Ciclopirox Generic 651 $23,381
Santyl Collagenase Clostridium Hist. Brand 17 $9,780
Clotrimazole Generic 38 $769
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 33 $430
Doxycycline Hyclate Generic 17 $328
Ammonium Lactate Generic 14 $290

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$72,017

Medicare's payments for the services billed

Medicare patients

326

Average age 75

Services billed

1,045

180 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 56%
Chronic kidney disease 55%
Ischemic heart disease 51%
Heart failure 33%
Depression 30%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $117
$117 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

563 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record